Avid inks new, expanded contract manufacturing agreements

The contract development and manufacturing organization (CDMO) Avid Bioservices recently signed two new service agreements to support the development of novel drug candidates. 

Under terms of the agreement with “a top ten pharmaceutical company by revenue,” the CDMO will provide process transfer and clinical manufacturing services to support the development of a novel therapeutic candidate, according to the company.

The unnamed company is a new customer for which Avid is immediately initiating process transfer of cell line and bench-scale information for the program. This is to be followed by 2,000-liter clinical manufacture of the compound.

Avid also will provide process development and clinical manufacturing services as part of a new agreement with an existing biotechnology customer. It is the company’s fourth compound for which the CDMO has been contracted to support.

According to the company, process development activities will support a 200-liter cGMP clinical manufacture of the compound.

Rick Hancock, interim president and CEO of Avid, said in a statement: “These two new manufacturing contracts represent key business development successes which serve to maintain the momentum we have established at Avid toward our dual goals of revenue growth and customer base diversification.”​

Avid was unable to provide any additional comment.